Atrys HealthXMAD:ATRY -0.97%66 PB Ratio is 1.28 as of Jun. 25, 2026, which is 21% below its 10-year median of 1.63. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.11 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,233 Biotechnology companies, Atrys Health ranks better than 76.07% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Atrys Health's share price is €2.565. Atrys Health's Book Value per Share for the quarter that ended in Dec. 2025 was €2.00. Hence, Atrys Health's PB Ratio of today is 1.28.
The historical rank and industry rank for Atrys Health's PB Ratio or its related term are showing as below:
XMAD:ATRY'
s PB Ratio Range Over the Past 10 Years
Min: 0.75 Med: 1.63 Max: 5.53
Current: 1.28
During the past 10 years, Atrys Health's highest PB Ratio was 5.53. The lowest was 0.75. And the median was 1.63.
XMAD:ATRY's PB Ratio is ranked better than 76.07% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs XMAD:ATRY: 1.28
During the past 12 months, Atrys Health's average Book Value Per Share Growth Rate was -40.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.30% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Atrys Health was 53.30% per year. The lowest was -23.30% per year. And the median was 22.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Atrys Health PB Ratio Related Terms
Atrys Health PB Ratio Historical Data
* Premium members only.
The historical data trend for Atrys Health's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Atrys Health's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's PB Ratio distribution charts can be found below:
* The bar in red indicates where Atrys Health's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Atrys Health's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Atrys Health (XMAD:ATRY) has a PB Ratio of 1.28 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Atrys Health and its competitors. This is 21% below median its historical median of 1.63. Over the past decade, Atrys Health's PB Ratio has ranged from 0.75 to 5.53. According to the industry distribution chart, Atrys Health ranks #295 out of 1233 companies in the Biotechnology industry, placing it in the top 23.9%.
Is Atrys Health's PB Ratio too high?
Atrys Health's current PB Ratio of 1.28 is 21% below median its 10-year median of 1.63. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 5.53. The Biotechnology industry median PB Ratio is 2.80. Atrys Health's value of 1.28 is 54.3% below this industry median. Based on the distribution chart, Atrys Health ranks #295 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #295 out of 1233 companies for PB Ratio. This places Atrys Health in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Atrys Health's value of 1.28 is 54.3% below this benchmark. Historically, Atrys Health's own PB Ratio has ranged from 0.75 to 5.53 over the past decade. While the company's 10-year median is 1.63 vs. the industry median of 2.80, Atrys Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrys Health's current PB Ratio of 1.28 is 54.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Atrys Health and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrys Health's current PB Ratio is 1.28, which is 21% below median its own 10-year median of 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.57 — trading 17.5% below its estimated fair value. The current PB Ratio is 1.28, which is 21% below median its 10-year median of 1.63 and 54.3% below the Biotechnology industry median of 2.80. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current PB Ratio is 1.28 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.57 is trading 17.5% below its estimated GF Value™ of €3.11.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
PB Ratio: 1.28 (21% below median its 10-year median of 1.63)
GF Value™: €3.11 vs. price of €2.57 (17.5% below fair value)
Industry Position: 54.3% below the Biotechnology median (#295 of 1233)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score
Get the complete analysis for XMAD:ATRY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
